Integrated BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
May 10, 2024 at 04:17 pm EDT
Share
Integrated BioPharma, Inc. reported earnings results for the third quarter and nine months ended March 31, 2024. For the third quarter, the company reported sales was USD 13.15 million compared to USD 13.1 million a year ago. Net income was USD 0.285 million compared to USD 0.016 million a year ago. Basic earnings per share from continuing operations was USD 0.01. Diluted earnings per share from continuing operations was USD 0.01.
For the nine months, sales was USD 37.57 million compared to USD 37.68 million a year ago. Net loss was USD 0.156 million compared to USD 0.074 million a year ago. Basic loss per share from continuing operations was USD 0.01. Diluted loss per share from continuing operations was USD 0.01.
Integrated Biopharma Inc. is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements, and herbal products. The Companyâs business segments include Contract Manufacturing operated by Manhattan Drug Company, Inc. (MDC), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; and Other Nutraceutical Businesses, which includes the operations of AgroLabs, Inc. (AgroLabs), The Vitamin Factory (the Vitamin Factory), IHT Health Products, Inc. (IHT), MDC Warehousing and Distribution, Inc., and Chem International, Inc. AgroLabs distributes healthful nutritional products for sale through mass market, grocery and drug and vitamin retailers under the brands: Peaceful Sleep, and Wheatgrass and other products. IHT is a distributor of fine natural botanicals, including multi-minerals produced under a license agreement. Chem is a distributor of raw materials.
INTEGRATED BIOPHARMA, INC. 
